About: Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 19 October 2018

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) im Oktober 2018 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'ochobre de 2018 (ast) наукова стаття, опублікована в жовтні 2018 (uk) scientific article published on 19 October 2018 (en)
publication date	wds:Q58586521-474DAE43-4D71-4697-B1DB-9EAD647A4E49
publication date	2018-10-19 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q58586521-41055347-19EA-450E-8346-922455A984D5
language of work or name	English
cites work	wds:Q58586521-03F703FD-2C15-4E62-9A3F-65DDE9BD3FC6 wds:Q58586521-0A7AFC50-B545-4264-8CA3-5FA530D56549 wds:Q58586521-1873ECD1-5D8E-4B8D-90B3-FEDFC617E0E2 wds:Q58586521-1DB7C9DC-603D-4513-ADA6-020773D7CC2B wds:Q58586521-23905805-905A-4CA4-86E5-D1E4EA63FF43 wds:Q58586521-42B86D40-D70A-415F-A605-EBF0D4F35755 wds:Q58586521-4D93E6FA-256E-4347-8353-E82E2E76FAA5 wds:Q58586521-4EE9E0BC-FF87-4EDF-B854-8FBBCC1FEF06 wds:Q58586521-4F2347FD-D7B8-4335-8F38-3696D2131516 wds:Q58586521-6088D443-A819-41F9-87C3-C2354A756222 wds:Q58586521-60A64361-BF8E-4D78-8872-0A4F5638B4AB wds:Q58586521-621D12F7-D21E-4768-AF90-EF9D701267BF wds:Q58586521-64A9DCFF-B3D0-428F-8789-98D4E1D8AB5A wds:Q58586521-64F11DDD-55C8-4A51-967A-C9167EA97EAC wds:Q58586521-69255486-5636-43D2-BEC6-B7DDD62B99F4 wds:Q58586521-7101A7D2-FCB0-4089-A774-100B4A9484C0 wds:Q58586521-714C920D-2900-4993-A857-16C0D33197B6 wds:Q58586521-8C301197-C4F9-4A97-94F6-946D07C40CE1 wds:Q58586521-8E6C1120-B2AC-4A55-9250-D8DE05A651D7 wds:Q58586521-984055AE-C163-41C9-A2E0-592694186276 wds:Q58586521-9B690E31-04BC-4E9B-A55C-36655EA4D137 wds:Q58586521-9DAF4F0E-1220-4662-A233-156078F5DFA1 wds:Q58586521-A910F2E6-97CA-4D18-979D-4FFFDE7D03BD wds:Q58586521-ACA6A091-F0EF-4E22-BB85-7B4DEF5DFC73 wds:Q58586521-B08B8467-4DF2-4973-A463-2220009CA7A3 wds:Q58586521-B948C83B-2A83-496B-9E61-AB577B63ED59 wds:Q58586521-BD403D78-BC19-4F6F-B70D-EE5F2B7CE7A7 wds:Q58586521-BF586CC7-9F16-4C0F-A1E3-7A7A8206255A wds:Q58586521-C1AF874A-253B-48BA-9B2A-6B51939E0BA1 wds:Q58586521-C2298FA3-05CF-4DB4-AE6F-DB3467758777 wds:Q58586521-C4809D72-67DD-4B9C-ABB8-05500B6B6FA7 wds:Q58586521-CDC36E79-8B77-4F2C-B88A-E61451F61ADE wds:Q58586521-D41000D8-8626-4E34-B5B6-FF6F82A8669D wds:Q58586521-DF98D483-689D-47BA-B3C2-09D485ED54E4 wds:Q58586521-E1C4F8F1-8E1F-4F65-AF22-DDEA6FF58411 wds:Q58586521-E5704A7B-822B-468B-B78B-A2D4D0F83634 wds:Q58586521-EB41E12A-07D6-4102-B0AF-9FAE5172B5C5 wds:Q58586521-F3D5A773-74C9-4A36-AFCD-60D20F7381D8
cites work	Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party o Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes Guidance on the management of diarrhoea during cancer chemotherapy Allogeneic peripheral blood stem cell transplantation is a promising and safe choice for the treatment of refractory/relapsed acute myelogenous leukemia, even with a higher leukemia burden Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in O Intensity adjustment of hematopoietic alogeneic transplantation in acute leukemia Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older. The Efficacy of Fludarabine, High Dose Cytosine Arabinoside with Granulocyte Colony Stimulating Factor (FLAG) Protocol as Salvage Therapy for Refractory/Relapsed Acute Leukemias in Adult Iraqi Patients Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT). Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial. A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial
author name string	wds:Q58586521-1ED714CA-4B01-4DD6-A783-0B047CEFEFBA wds:Q58586521-39BB48C1-294F-4C5B-BF12-97E91CC4D8E4 wds:Q58586521-39E3AD18-925D-454B-B192-641CED8469BE wds:Q58586521-42A12799-C9FC-4B12-8FD3-C1C2F408E067 wds:Q58586521-5E8FDE3B-A25B-43CD-9F9B-C556481BD6EC wds:Q58586521-63240014-18A7-47F0-A80B-1B5EE7A2E8F2 wds:Q58586521-727157A8-FA07-4E5B-A5FC-C53AD847507B wds:Q58586521-781AB96F-B134-4F92-B0CB-BE00878A66D8 wds:Q58586521-7DD50080-A2F9-4387-946F-9E2FE335286B wds:Q58586521-9233ED31-3E99-4B3D-8B10-B16633835288 wds:Q58586521-9CACD7EC-EAEA-47DB-A7A5-EABFD45FD28B wds:Q58586521-B6891527-E187-4B59-9B08-86C4EB2D213A wds:Q58586521-BAFB6B3E-1209-41D0-9336-CA8024F136A1 wds:Q58586521-DA35ABB9-4951-4F5F-8DDB-FC933731867C

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software